Compare VCEL & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | WD |
|---|---|---|
| Founded | 1989 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 1996 | 2010 |
| Metric | VCEL | WD |
|---|---|---|
| Price | $32.55 | $46.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $58.50 | ★ $78.33 |
| AVG Volume (30 Days) | ★ 416.0K | 410.4K |
| Earning Date | 05-18-2026 | 05-29-2026 |
| Dividend Yield | N/A | ★ 5.76% |
| EPS Growth | ★ 60.00 | N/A |
| EPS | 0.32 | ★ 1.64 |
| Revenue | $276,259,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | $19.09 | $20.09 |
| Revenue Next Year | $17.96 | $7.82 |
| P/E Ratio | $102.78 | ★ $28.75 |
| Revenue Growth | ★ 16.45 | 8.99 |
| 52 Week Low | $29.24 | $42.12 |
| 52 Week High | $48.75 | $90.00 |
| Indicator | VCEL | WD |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 33.36 |
| Support Level | $31.34 | $42.12 |
| Resistance Level | $38.48 | $66.25 |
| Average True Range (ATR) | 1.37 | 3.22 |
| MACD | -0.39 | -0.53 |
| Stochastic Oscillator | 3.03 | 24.92 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.